Match!

Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinoma

Published on Dec 1, 2013in Radiation Oncology2.895
路 DOI :10.1186/1748-717X-8-82
Vassilis Kouloulias21
Estimated H-index: 21
(NTUA: National Technical University of Athens),
T. Kalogeropoulos2
Estimated H-index: 2
+ 8 AuthorsNikolaos Kelekis29
Estimated H-index: 29
Abstract
Objective To evaluate the feasibility of the transperineal implementation of biocompatible balloon (Prospace) and the acute toxicity of high dose 3DCRT in patients with localized low risk prostate cancer.
  • References (42)
  • Citations (6)
馃摉 Papers frequently viewed together
23 Authors (Eliahu Gez, ..., Madhur K. Garg)
24 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
References42
Newest
Purpose To report the clinical outcome of high-dose-rate (HDR) interstitial (IRT) brachytherapy (BRT) as sole treatment (monotherapy) for clinically localized prostate cancer. Methods and Materials Between January 2002 and December 2009, 718 consecutive patients with clinically localized prostate cancer were treated with transrectal ultrasound (TRUS)-guided HDR monotherapy. Three treatment protocols were applied; 141 patients received 38.0 Gy using one implant in 4 fractions of 9.5 Gy with compu...
100 CitationsSource
#1Rupesh Kotecha (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
#2Yoshiya Yamada (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 54
Last. Michael J. Zelefsky (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 94
view all 8 authors...
Abstract Purpose To report prostate-specific antigen (PSA) relapse-free survival and treatment-related toxicity outcomes after combining high-dose-rate (HDR) brachytherapy with external beam radiotherapy (EBRT) for patients with clinically localized prostate cancer. Methods and Materials Between 1998 and 2009, 229 patients were treated with HDR brachytherapy followed 3 weeks later by supplemental EBRT. The HDR brachytherapy boost consisted of three fractions of 192 Ir (5.5鈥7.5聽Gy per fraction), ...
40 CitationsSource
#1A. MagliH-Index: 2
#2M. Giangreco (University of Udine)H-Index: 1
Last. S. FongioneH-Index: 1
view all 9 authors...
Purpose Erectile dysfunction is associated with all the common treatment options for prostate cancer. The aim of this research was to evaluate the relationship between erectile function and radiation dose to the penile bulb (PB) and other proximal penile structures in men receiving conformal radiotherapy (CRT) without hormonal therapy (HT) for prostate cancer, whose sexual function was known before treatment.
14 CitationsSource
#2Michael LotterH-Index: 20
Last. Vratislav StrnadH-Index: 28
view all 6 authors...
Abstract Purpose We reviewed our seven year single institution experience with pulsed dose rate brachytherapy dose escalation study in patients with intermediate and high risk prostate cancer. Materials and methods We treated a total of 130 patients for intermediate and high risk prostate cancer at our institution between 2000 and 2007 using PDR-brachytherapy as a boost after conformal external beam radiation therapy to 50.4Gy. The majority of patients had T2 disease (T1c 6%, T2 75%, T3 19%). Se...
21 CitationsSource
#1Curtiland Deville (UPenn: University of Pennsylvania)H-Index: 19
#2Stefan BothH-Index: 5
Last. Neha VapiwalaH-Index: 21
view all 8 authors...
Background: Our purpose was to report acute gastrointestinal (GI) and genitourinary (GU) toxicity rates for prostate cancer patients undergoing image-guided intensity modulated radiation therapy (IG-IMRT) with a daily endorectal water-filled balloon (ERBH2O), and assess associations with planning parameters and pretreatment clinical characteristics. Methods: The first 100 patients undergoing prostate and proximal seminal vesicle IG-IMRT with indexed-lumen 100 cc ERBH2O to 79.2 Gy in 1.8 Gy fract...
11 CitationsSource
#1Zumre Arican Alicikus (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
#2Yoshiya Yamada (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 54
Last. Michael J. Zelefsky (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 94
view all 8 authors...
BACKGROUND. The authors investigated long-term tumor control and toxicity outcomes after high-dose, intensity-modulated radiation therapy (IMRT) in patients who had clinically localized prostate cancer. METHODS. Between April 1996 and January 1998, 170 patients received 81 gray (Gy) using a 5-field IMRT technique. Patients were classified according to the National Comprehensive Cancer Network-defined risk groups. Toxicity data were scored according to the Common Terminology Criteria for Adverse ...
158 CitationsSource
7 Citations
#1Pirus Ghadjar (University of Bern)H-Index: 24
#2Nicole Gwerder (University of Bern)H-Index: 2
Last. Daniel M. Aebersold (University of Bern)H-Index: 24
view all 7 authors...
to report acute and late toxicity in prostate cancer patients treated by high-dose intensity-modulated radiation therapy (IMRT) with daily image-guidance.
21 CitationsSource
#1Anna Wilkins (The Royal Marsden NHS Foundation Trust)H-Index: 6
#2Chris Parker (The Royal Marsden NHS Foundation Trust)H-Index: 70
This Review focuses on the adverse effects of radical radiotherapy for localized prostate cancer. The authors discuss the methodological issues that make comparison between the different treatment modalities problematic, and describe the pattern of adverse effects that occur over time after radiotherapy. Recent technical advances, such as intensity modulation and image guidance, will hopefully further improve the toxicity profile of prostate radiotherapy.
11 CitationsSource
#1S HummelH-Index: 4
#2Emma SimpsonH-Index: 18
Last. Angie ReesH-Index: 15
view all 5 authors...
64 CitationsSource
Cited By6
Newest
#1Ben G. L. VannesteH-Index: 10
#2Kees van de Beek (UM: Maastricht University)H-Index: 2
Last. Philippe LambinH-Index: 81
view all 4 authors...
6 CitationsSource
#1Daniel M. Trifiletti (UVA: University of Virginia)H-Index: 11
#2Allison Garda (UVA: University of Virginia)H-Index: 3
Last. Timothy N. Showalter (UVA: University of Virginia)H-Index: 22
view all 3 authors...
ABSTRACTIntroduction: Recent clinical advances in radiation therapy have aimed to improve the therapeutic ratio through shortening the treatment duration through increasing the biologically effective dose (either through dose escalation or hypofractionation). However, despite using advanced techniques such as intensity modulated radiation therapy (IMRT) and image-guidance methods, dose escalation can be limited by its resultant gastrointestinal toxicity. In an effort to reduce rectal toxicity, b...
4 CitationsSource
#1Moon Hyung KangH-Index: 4
#2Young Dong YuH-Index: 3
Last. Dong Soo ParkH-Index: 9
view all 5 authors...
To investigate the difference in rectal complications rate following prostate low dose rate (LDR) brachytherapy based on prostate-rectum distance and prostate longitudinal length among early prostate cancer patients.From March 2008 to February 2013, 245 prostate cancer patients with a Gleason score 鈮7 were treated with 125-I LDR brachytherapy. Among them, 178 patients with prostate volume 20-35 mL and a follow-up period 鈮6 months were evaluated for radiation proctitis. Magnetic resonance imaging...
4 CitationsSource
1 Citations
#1Heather Payne (UCL: University College London)H-Index: 9
#2Vincent Khoo (The Royal Marsden NHS Foundation Trust)H-Index: 46
Last. Roger KirbyH-Index: 37
view all 11 authors...
One of the most challenging areas of prostate cancer is the management of patients with high-risk localised or locally advanced disease (stage T3-T4, Nx-N0, M0; Figure 1). The problem with a single definition, such as that of D鈥橝mico,1 is that it does not take into consideration the heterogeneity of this group of patients whose post-surgical pathological T stage can be higher or lower.2,3 In addition, it does not consider indicators of disease load, such as biopsy core involvement or occult lymp...
Source
ABSTRACT: Definitive radiotherapy is a well-recognized treatment option for localized prostate cancer. Rectum toxicity is the dose-limiting toxicity. Dose鈥搗olume correlations have been reported in many studies. The application of a spacer to increase the distance between the prostate and anterior rectal wall is an innovative technique, considerably reducing the dose to the rectum. Hyaluronic acid, human collagen, an inflatable balloon or hydrogel are potential materials to create the desired eff...
14 CitationsSource